ABAXIS ANNOUNCES CLIA WAIVED STATUS

ABAXIS, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that the U.S. Food and Drug Administration has granted waived status under CLIA regulations for three additional analytes -- ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase) and Glucose -- when used in conjunction with the Piccolo point of care analyzer.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-25-2005/0004094164&EDATE)